CD8A and neoplasm: The premise of cancer immunotherapy is that activation of the immune system can drive CD8+ cytotoxic T-lymphocytes (CTL) to recognize tumour-associated antigens (TAAs) and kill cancerous cells, thereby slowing, or even reversing, tumour growth.